Objective: To assess intermittent abdominal pain in IgA vasculitis patients and its relation to demographic data, clinical manifestations and treatments.

Methods: A retrospective cohort study included 322 patients with IgA vasculitis (EULAR/PRINTO/PRES criteria) seen at the Pediatric Rheumatology Unit in the last 32 years. Sixteen patients were excluded due to incomplete data in medical charts. Intermittent abdominal pain was characterized by new abdominal pain after complete resolution in the first month of disease.

Results: Intermittent abdominal pain was observed in 35/306 (11%) IgA vasculitis patients. The median time between first and second abdominal pain was 10 days (3–30 days). The main treatment of intermittent abdominal pain included glucocorticoid [n=26/35 (74%)] and/or ranitidine [n=22/35 (63%)]. Additional analysis showed that the frequency of intermittent purpura/petechiae (37 vs. 21%; p=0.027) and the median of purpura/petechiae duration [20 (3–90) vs. 14 (1–270) days; p=0.014] were significantly higher in IgA vasculitis patients with intermittent abdominal pain compared to those without. Gastrointestinal bleeding (49 vs. 13%; p<0.001), nephritis (71 vs. 45%; p=0.006), glucocorticoid (74 vs. 44%; p=0.001) and intravenous immunoglobulin use (6 vs. 0%; p=0.036) were also significantly higher in the former group. The frequency of ranitidine use was significantly higher in IgA vasculitis patients with intermittent abdominal pain versus without (63 vs. 28%; p<0.001), whereas the median of ranitidine duration was reduced in the former group [35 (2–90) vs. 60 (5–425) days; p=0.004].

Conclusions: Intermittent abdominal pain occurred in nearly a tenth of IgA vasculitis patients, in the first 30 days of disease, and was associated with other severe clinical features. Therefore, this study suggests that these patients should be followed strictly with clinical and laboratory assessment, particularly during the first month of disease course.

Keywords: Immunoglobulin A; Abdominal pain; Henoch-Schönlein purpura; Glucocorticoid; Ranitidine.

Objetivo: Avaliar a dor abdominal intermitente em pacientes com vasculite por IgA e sua relação com dados demográficos, manifestações clínicas e tratamentos.

Métodos: Um estudo de coorte retrospectiva incluiu 322 pacientes com vasculite por IgA (critérios EULAR/PRINTO/PRES) em uma Unidade de Reumatologia Pediátrica durante 32 anos. Dezessete pacientes foram excluídos em razão de dados incompletos. A dor abdominal intermitente foi caracterizada por nova dor abdominal difusa após resolução completa no primeiro mês da doença.

Resultados: Dor abdominal intermitente foi observada em 35/306 (11%) dos pacientes com vasculite por IgA. A mediana entre a primeira e a segunda dor abdominal foi 10 dias (3–30 dias). O principal tratamento incluiu glicocorticoide [n=26/35 (74%)] e/ou ranitidina [n=22/35 (63%)]. Análises adicionais mostraram que a frequência da púrpura/petéquia intermitente (37 vs. 21%; p=0,027) e a mediana da duração da púrpura/petéquia [20 (3–90) vs. 14 (1–270) dias; p=0,014] foram significativamente maiores em pacientes com vasculite por IgA com dor abdominal intermitente em comparação com aqueles sem essa condição. Sangramento gastrointestinal (49 vs. 13%; p<0,001), nefrite (71 vs. 45%; p=0,006), uso de glicocorticoides (74 vs. 44%; p=0,001) e de imunoglobulina endovenosa (6 vs. 0%; p=0,036) também foram maiores no primeiro grupo. A frequência do uso de ranitidina foi significativamente maior em pacientes com vasculite por IgA com dor abdominal intermitente versus sem dor (63 vs. 28%; p<0,001), ao passo que a mediana da duração do uso de ranitidina foi reduzida no primeiro grupo [35 (2–90) vs. 60 (5–425) dias; p=0,004].

Conclusões: Dor abdominal intermitente ocorre em, aproximadamente, um décimo dos pacientes com vasculite por IgA, nos primeiros 30 dias da doença, e foi associada a manifestações clínicas graves. Este estudo sugere, portanto, que esses pacientes devem ser seguidos rigorosamente com avaliação clínica e laboratorial, principalmente durante o primeiro mês da doença.

Palavras-chave: Imunoglobulina A; Dor abdominal; Púrpura Henoch-Schönlein; Glucocorticoides; Ranitidina.
INTRODUCTION

Immunoglobulin A (IgA) vasculitis, previously termed as Henoch-Schönlein purpura, is the most frequent primary vasculitis reported in children and adolescents’ populations.1,5 This vasculitis is characterized by skin, articular, renal and gastrointestinal involvements.1-6

Acute onset of diffuse colicky abdominal pain has been described in up to 12% of IgA vasculitis patients at diagnosis. This gastrointestinal manifestation may be associated with serious complications, as bowel intussusception or gastrointestinal bleeding.1,2

Of note, recurrent or intermittent colicky abdominal pain in IgA vasculitis were seldom described in previous case reports or case series.1,2,7-11 However, to our knowledge, additional analysis comparing patients with versus patients without intermittent abdominal pain in the first month of IgA vasculitis were not carried out.

Thus, the aim of the present study was to characterize intermittent colicky abdominal pain in the first month of children and adolescents with IgA vasculitis, and to assess the possible association of demographic data, clinical manifestations, laboratory abnormalities and treatments in patients with and without this gastrointestinal manifestation.

METHOD

A retrospective cohort study was performed during a period of 32 years in a tertiary Pediatric Rheumatology Unit in São Paulo, Brazil. We analyzed 322 medical records. Of these, 16 were excluded due to lack of data. The remaining 306 patients fulfilled European League Against Rheumatism (EULAR), Paediatric Rheumatology International Trials Organisation (PRINTO) and Paediatric Rheumatology Europe Society (PRES) IgA vasculitis classification criteria.6 This study was approved by the Local Ethics Committee.

Demographic data, such as age at diagnosis in years, gender and body mass index (BMI), were evaluated.

Abdominal pain was defined as diffuse colicky abdominal pain with acute onset assessed by medical history and physical exam. Severe abdominal pain was described as the presence of at least one of the subsequent: abdominal angina (severe postprandial diffuse colicky abdominal pain),12 bowel intussusception or gastrointestinal bleeding. Intermittent abdominal pain was arbitrarily identified herein as a new episode of diffuse colicky abdominal ache after the complete resolution of the first event, both episodes occurring in the first month of disease.10,11 Recurrent abdominal pain was defined as another flare of abdominal pain after the first month of disease. Abdominal Doppler ultrasound was performed in those IgA vasculitis patients with gastrointestinal bleeding.1 The time between first and second diffuse colicky abdominal pain was also evaluated.

Intermittent purpura/petechiae were characterized as new skin lesions after total recovery of first episode, and persistent purpura/petechiae as cutaneous lesions lasting more than 30 days. The definition of arthritis was joint pain with limitation on movement or articular edema. Arthralgia was defined by articular pain without edema or limitation on motion.1-3 Intermittent arthralgia/arthritis, as new onset articular inflammation after total resolution.1,3 Orchitis was described as the presence of scrotal swelling and/or tenderness in physical exam and/or testicular Doppler ultrasound alterations.2 The duration of orchitis was measured in days.

Nephritis was defined as hematuria >5 red blood cells/high power field or presence of red blood cells in the urinary sediment and/or proteinuria >0.1g/m2/day. Nephrotic syndrome was diagnosed according to edema, serum albumin <2.5g/L and proteinuria >1g/m2/day.3 Acute kidney injury was characterized by increase in serum creatinine >2mg/dL13 or according to modified RIFLE (Risk, Injury, Failure, Loss of renal function and End-stage renal disease) criteria.14 Arterial hypertension was categorized as systolic and/or diastolic blood pressure >95th percentile according to gender, age, and height on 3 or more occasions.15

Neuropsychiatric involvement was characterized by the presence of at least one of the following manifestations: headache, impaired consciousness, seizures, hemiparesis and cortical blindness.16 Current drugs were also recorded: prednisone/prednisolone, intravenous methylprednisolone, ranitidine, intravenous immunoglobulin (IVIG), azathioprine, cyclosporine, intravenous cyclophosphamide (IVCYC) and plasmapheresis.

Patients with IgA vasculitis were divided into two groups: with and without intermittent abdominal pain in the first month of disease course.

Results were presented as median (range) or mean±standard deviation for continuous variables, and number (%) for categorical variables. Pearson’s chi-square or Fisher’s exact tests were used to compare categorical variables. Mann-Whitney test or Student’s t-test were used to compare continuous variables. For all statistical tests, a p-value less than 0.05 was considered with statistical significance.

RESULTS

Intermittent abdominal pain in the first month of disease was observed in 35/306 (11%) of IgA vasculitis patients, and generally reported as colicky and diffuse abdominal pain. This intermittent abdominal pain was associated with
new cutaneous lesions in the first month of disease in 32/35 (91%) of IgA vasculitis patients. The median time between the first and the second episode of abdominal pain was 10 days (3–30 days). The main treatment of intermittent abdominal pain included glucocorticoid [n=26/35 (74%)] and/or ranitidine [n=22/35 (63%)]. Only one IgA vasculitis patient had recurrent abdominal pain at 5 year of disease. At that moment, he reported colicky and diffuse abdominal pain, concomitantly with new cutaneous lesions and nephritis flare.

Table 1 includes demographic data and clinical/laboratory involvements in 306 IgA vasculitis patients with intermittent abdominal pain compared to those without this condition.

Table 1  Demographic data and clinical/laboratory involvements in 306 IgA vasculitis patients with intermittent abdominal pain compared to those without this condition.

| Variables at diagnosis, n (%)                  | With intermittent abdominal pain (n=35) | Without intermittent abdominal pain (n=271) | p-value |
|-----------------------------------------------|----------------------------------------|------------------------------------------|---------|
| Demographic data                              |                                        |                                          |         |
| Age at diagnosis, years                        | 7.3 (2.2–13.1)                         | 6 (1.25–17.6)                            | 0.073   |
| Follow-up duration, months                     | 12 (1–180)                             | 12 (0–180)                               | 0.248   |
| Female, n=305                                  | 16/35 (46)                             | 131/270 (48)                             | 0.859   |
| Body mass index, kg/m2                         | 15.9 (12.3–28.4)                       | 16.1 (10.6–32.7)                         | 0.728   |
| Clinical/laboratorial involvements             |                                        |                                          |         |
| Intermittent purpura/petechiae, n=303          | 13/35 (37)                             | 55/268 (21)                              | 0.027   |
| Purpura/petechiae duration, days               | 20 (3–90)                              | 14 (1–270)                               | 0.014   |
| Arthritis/arthralgia, n=305                    | 26/35 (74)                             | 214/270 (79)                             | 0.499   |
| Intermittent arthritis/arthralgia, n=305       | 4/35 (4)                               | 15/270 (6)                               | 0.252   |
| Arthritis/arthralgia duration, days            | 4 (1–30)                               | 5 (0–28)                                 | 0.842   |
| Abdominal pain, n=305                          | 35/35 (100)                            | 153/270 (57)                             | <0.001  |
| Severe abdominal pain, n=184                   | 21/35 (60)                             | 43/149 (29)                              | <0.001  |
| Gastrointestinal bleeding, n=303               | 17/35 (49)                             | 34/268 (13)                              | <0.001  |
| Bowel intussusception                          | 1/35 (3)                               | 0/271 (0)                                | 0.115   |
| Nephritis, n=296                               | 24/34 (71)                             | 119/262 (45)                             | 0.006   |
| Arterial hypertension, n=256                   | 7/30 (23)                              | 32/226 (15)                              | 0.185   |
| Nephrotic syndrome, n=297                      | 1/35 (3)                               | 3/262 (1)                                | 0.396   |
| Acute kidney injury, n=291                     | 0/34 (0)                               | 5/257 (2)                                | 1.000   |
| Leukocyturia, n=295                            | 8/34 (23)                              | 45/261 (17)                              | 0.396   |
| Urinary casts, n=295                           | 3/34 (8)                               | 22/261 (8)                               | 1.000   |
| Hematuria, n=295                               | 19/34 (56)                             | 65/261 (25)                              | <0.001  |
| Proteinuria, n=223                             | 15/29 (52)                             | 73/194 (38)                              | 0.159   |
| Neuropsychiatric involvement, n=305            | 0/35 (0)                               | 1/270 (0)                                | 1.000   |
| Increased serum IgA (>255mg/dL), n=168         | 9/20 (45)                              | 57/148 (38)                              | 0.577   |
| Orchitis, n=305                                | 3/35 (9)                               | 24/270 (9)                               | 1.000   |
| Orchitis duration, days                        | 4 (3–7)                                | 4 (1–17)                                 | 0.842   |

Results are presented as median (minimum value–maximum value) or n (%).
were also significantly higher in IgA vasculitis patients with *versus* without intermittent abdominal pain. The median of glucocorticoid therapy duration was higher in the first group [72.5 (1–365) vs. 40 (1–144) days; *p*=0.012]. The frequency of ranitidine use was significantly higher in IgA vasculitis patients with intermittent abdominal pain *versus* without (63 vs. 28%; *p*<0.001), whereas the median of ranitidine therapy duration was reduced in the former group [35 (2–90) vs. 60 (5–425) days; *p*=0.004] (Table 2).

**DISCUSSION**

To our knowledge, this was the first study that demonstrated intermittent abdominal pain in the first month of disease as a rare manifestation of IgA vasculitis patients and was associated with skin manifestations, nephritis and severe gastrointestinal involvement. In addition, recurrent abdominal pain was rarely observed in IgA vasculitis patients.

The advantage of the present study was the selection of this population followed in a tertiary center in Latin America with predominance of complex patients. Moreover, all subjects fulfilled the validated EULAR/PRINTO/PRES classification criteria and were systematically assessed according to our standardized database, as previously reported.

At disease onset, approximately three quarters of our IgA vasculitis patients with intermittent abdominal pain had nephritis, suggesting a severe and periodic systemic involvement of this vasculitis. Indeed, nephritis is also commonly associated with IgA vasculitis flares, as reported in a study with Finland population.

Additionally, intermittent abdominal pain occurred in the first 30 days of IgA vasculitis patients. Therefore, these patients should be followed strictly with clinical and laboratorial assessment, particularly during the first month of disease course.

Regarding treatment, ranitidine showed to be effective in gastrointestinal manifestations in IgA vasculitis patients, decreasing duration and severity of gastrointestinal pain and bleeding as described in a Turkish research. Our study demonstrated that, in spite of a higher use of ranitidine in IgA vasculitis patients with intermittent abdominal pain, the ranitidine use duration was reduced, suggesting that this H2-receptor antagonist seem to be a protective factor for this periodic abdominal pain.

Of note, recently US Food and Drug Administration alerts to healthcare professionals that ranitidine contains low levels of nitrosamine impurity called N-nitrosodimethylamine (NDMA). This substance is identified as a probable human carcinogen, and the risk and benefit should be individually considered for each patient. Further studies will be necessary to clarify this issue.

Moreover, glucocorticoid use is indicated for severe and complicated abdominal pain in IgA vasculitis patients. Our study demonstrated that IgA vasculitis patients with intermittent abdominal pain required this medication more frequently and for a longer period.

The median time between the first and second episode of intermittent diffuse colicky abdominal pain was short, and the vast majority of patients associated with new cutaneous lesions, indicating that this pain etiology was probably due to disease activity. The diagnosis of abdominal pain in IgA vasculitis is usually easy and rarely requires a differential diagnosis with esophagitis, gastritis or gastric ulcer.

The main limitation observed in the present study was the retrospective analysis, with potential missing data. We also did not assess the serum galactose-deficient IgA1, a well-known biomarker of IgA vasculitis associated with severe abnormalities at diagnosis. Abdominal Doppler ultrasound was only assessed in those IgA vasculitis patients with gastrointestinal bleeding.

| Treatments, n (%) | Number of studied patients | With intermittent abdominal pain (n=35) | Without intermittent abdominal pain (n=271) | p-value |
|-------------------|----------------------------|-----------------------------------------|--------------------------------------------|---------|
| Glucocorticoid    | 305                        | 26/35 (74)                             | 119/270 (44)                               | 0.001   |
| Prednisone/prednisolone (mg/kg/day) | 1.8 (1–2)                  | 1.5 (0–3)                              |                                            | 0.801   |
| Glucocorticoid (days of use) | 72.5 (1–365)               | 40 (1–144)                             |                                            | 0.012   |
| Ranitidine        | 304                        | 22/35 (63)                             | 76/269 (28)                                | <0.001  |
| Ranitidine (days of use) | 35 (2–90)                  | 60 (5–425)                             |                                            | 0.004   |
| Immunosuppressive agents** | 305                        | 1/35 (3)                               | 0/270 (0)                                 | 0.115   |
| Intravenous immunoglobulin | 305                        | 2/35 (6)                               | 1/270 (0)                                 | 0.036   |

Results are presented as median (minimum value - maximum value) or n (%). *In the first month of disease; **azathioprine, cyclosporine or intravenous cyclophosphamide.
In conclusion, intermittent abdominal pain occurred in nearly a tenth of IgA vasculitis patients, in the first 30 days of disease, and was associated with other severe clinical features. Therefore, our study suggests that these patients should be followed strictly with clinical and laboratorial assessment, particularly during the first month of disease course.

Funding
This study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq 303422/2015-7 to CAS), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2015/03756-4 to CAS) and by Núcleo de Apoio à Pesquisa “Saúde da Criança e do Adolescente” da USP (NAP-CriAd) to CAS.

Conflict of interests
The authors declare there is no conflict of interests.

Declaration
The database that originated the article is available with the corresponding author.

Authors’ contributions
Study design: Silva CA. Data collection: Simon JR. Data analysis: Buscatti IM, Simon JR, Silva CA. Manuscript writing: Buscatti IM, Simon JR, Viana VS, Arabi T, Trindade VC, Maia AC, Melo LR, Ihara B, Aikawa NE, Silva CA. Manuscript revision: Buscatti IM, Simon JR, Viana VS, Arabi T, Trindade VC, Maia AC, Melo LR, Ihara B, Aikawa NE, Silva CA. Study supervision: Silva CA.

REFERENCES

1. Buscatti IM, Casella BB, Aikawa NE, Watanabe A, Farhat SC, Campos LM, et al. Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center. Clin Rheumatol. 2018;37:1319-24. https://doi.org/10.1007/s10067-017-3972-3

2. Buscatti IM, Abrão HM, Kozu K, Marques VL, Gomes RC, Sallum AM, et al. Characterization of scrotal involvement in children and adolescents with IgA vasculitis. Adv Rheumatol. 2018;58:38. https://doi.org/10.1186/s42358-018-0039-3

3. Almeida JL, Campos LM, Paim LB, Leone C, Koch VH, Silva CA. Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. J Pediatr. 2007;83:259-66. https://doi.org/10.2223/jped.1638

4. Rabelo Jr CR, Yamaguti R, Ribeiro AM, Melo BA, Campos LA, Silva CA. Hemorrhagic vesicle-bullous lesions in Henoch-Schönlein purpura and review of literature. Acta Reumatol Port. 2008;33:452-6.

5. Suehiro RM, Soares BS, Eisencraft AP, Campos LM, Silva CA. Acute hemorrhagic edema of childhood. Turk J Pediatr. 2007;49:189-92.

6. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798-806. https://doi.org/10.1136/ard.2009.116657

7. Pabunruang W, Treepongkaruna S, Tangnaranatchakit K, Chunharas A, Phuapradit P. Henoch-Schönlein purpura: clinical manifestations and long-term outcomes in Thai children. J Med Assoc Thai. 2002;85(Suppl 4):S1213-8.

8. Chou T, Louissant VR, Adams A, Gurkan S, Che Fitz D, Weller AS, et al. Successful treatment of Henoch-Schönlein purpura with recurrent gastrointestinal involvement with mycophenolate mofetil: a brief report. Clin Pediatr (Philad). 2015;54:900-3. https://doi.org/10.1177/0009922814568288

9. Lim CJ, Chen JH, Chen WL, Shen YS, Huang CC. Jejunoejenum intussusception as the single initial manifestation of Henoch-Schönlein purpura in a teenager. Am J Emerg Med. 2012;30:2085.E1-2085.E3. https://doi.org/10.1016/j.ajem.2011.12.003

10. Karakayali B, Yılmaz Ş, Çakir D, Günes PG, Güven S, İskel I. Henoch-Schönlein purpura associated with primary active Epstein-Barr virus infection: a case report. Pan Afr Med J. 2017;27:29. https://doi.org/10.11604/pamj.2017.27.29.10481

11. Belman AL, Leicher CR, Moshé SL, Mezey AP. Neurologic manifestations of Schönlein-Henoch purpura: report of three cases and review of the literature. Pediatrics. 1985;75:687-92.

12. Gomes RC, Marques VL, Cavalcante EG, Campos LA, Sallum AM, Silva CA, et al. Severe intestinal involvement as initial manifestation of systemic childhood polyarteritis nodosa: report of two cases. J Pediatr Surg. 2013;48:425-8. https://doi.org/10.1016/j.jpedsurg.2012.10.057

13. Chan JC, Williams DM, Roth KS. Kidney failure in infants and children. Pediatr Rev. 2002;23:47-60. https://doi.org/10.1542/pir.23-2-47

14. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028-35. https://doi.org/10.1038/sj.ki.5002231

15. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904. https://doi.org/10.1542/peds.2017-3035
16. Pacheva IH, Ivanov IS, Stefanova K, Chepisheva E, Chochkova L, Grozeva D, et al. Central nervous system involvement in Henoch-Schönlein purpura in children and adolescents. Case Rep Pediatr. 2017;2017:5483543. https://doi.org/10.1155/2017/5483543

17. Passone CG, Grisi SJ, Farhat SC, Manna TD, Pastorino AC, Alveno RA, et al. Complexity of pediatric chronic disease: cross-sectional study with 16,237 patients followed by multiple medical specialties. Rev Paul Pediatr. 2019;38:e2018101. https://doi.org/10.1590/1984-0462/2020/38/2018101

18. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Ankoski P, Hölttä T, et al. Clinical course of extrarenal symptoms in Henoch-Schönlein purpura: a 6-month prospective study. Arch Dis Child. 2010;95:871-6. https://doi.org/10.1136/adc.2009.167874

19. Narin N, Akçoral A, Aslin MI, Elmastas H. Ranitidine administration in Henoch-Schönlein vasculitis. Acta Paediatr Jpn. 1995;37:37-9. https://doi.org/10.1111/j.1442-200x.1995.tb03682.x

20. U.S. Food and Drug Administration [homepage on the Internet]. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. New Hampshire (US): U.S. Food and Drug Administration; 2019 [cited 2020 Feb 17]. Available from: https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine.

21. Mahase E. FDA recalls ranitidine medicines over potential cancer causing impurity. BMJ. 2019;367:l5832. https://doi.org/10.1136/bmj.l5832

22. Rosenblum ND, Winter HS. Steroid effects on the course of abdominal pain in children with Henoch-Schönlein purpura. Pediatrics. 1987;79:1018-21.

23. Pillebout E, Jamin A, Ayari H, Housset P, Pierre M, Sauvaget V, et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One. 2017;12:e0188718. https://doi.org/10.1371/journal.pone.0188718